Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.

Specific PHGKB|Cancer|PHGKB

Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Dec 17, 2017

---

• Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.  
  Kim Annette S et al. JAMA oncology 2017 Dec
• Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. 
  Gschwantler-Kaulich Daphne et al. PloS one 2017 (12) e0189641
• Germline BRCA mutation in male carriers-ripe for precision oncology?  
  Leão Ricardo Romão Nazário et al. Prostate cancer and prostatic diseases 2017 Dec
• Precision Medicine and Testing for Tumor Biomarkers—Are All Tests Born Equal?  
  DF Hayes, JAMA Oncology, Dec 14, 2017
• Professionals' knowledge, attitude and referral behaviour of preimplantation genetic diagnosis for hereditary breast and ovarian cancer.  
  Gietel-Habets J J G et al. Reproductive biomedicine online 2017 Dec
• I Am Alive and Kickin: An Interview With Lynch Syndrome and Colon Cancer Survivor David Dubin  
  The Colon Cancer Podcast, Nov 2017
• What to Know Before Buying a Home DNA Test  
  American Cancer Society, Dec 14, 2017
• Recommendations for genetic counseling and genetic testing for hereditary prostate cancer  
  Medical Xpress, Dec 13, 2017
• Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017  
  VN Giri et al, J Clin Onc, Dec 13, 2017
• A Milestone for CAR T Cells.  
  Tran Eric et al. The New England journal of medicine 2017 Dec